Coming fresh on the heels of perceived problems concerning Cox-2 inhibitors, the decision by the drug's makers and the FDA to withdraw Tysabri from the market soon after the death of a patient could signal the beginning of an era of faster responses to safety and legal problems drugs may cause. A member of the Washington Analysis research group said the "semi-hysteria over drug safety" probably had as much influence on the response as anything else.

Full Story:

Related Summaries